Asahi shares mark weekly slide after cyberattack halts production
Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider sold 1,462 shares of common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The weighted average price for the transaction was $18.8632, with prices ranging from $18.58 to $19.09. The stock currently trades at $20.10, near its 52-week high of $24.50, with InvestingPro data showing strong momentum over the past month.
The total value of the shares sold amounted to $27,577. Following the transaction, Feider directly owns 44,041 shares of Beta Bionics, Inc. (BBNX), which currently has a market capitalization of $819 million. Analysts maintain a bullish outlook, with price targets ranging from $17 to $30.
The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units. InvestingPro analysis reveals 8 additional key insights about BBNX’s financial health and market position, available exclusively to subscribers through the comprehensive Pro Research Report.
In other recent news, Beta Bionics Inc . reported its second-quarter earnings for 2025, revealing significant financial improvements. The company recorded an earnings per share (EPS) of -$0.39, surpassing the forecasted -$0.42. Net sales saw a 54% year-over-year increase, reaching $23.2 million, which contributed to the positive earnings surprise. Truist Securities responded by raising its price target for Beta Bionics to $21.00 from $18.00, while maintaining a Buy rating. This adjustment was attributed to the company’s strong revenue and gross margin performance, driven by above-consensus new patient starts and success in the pharmacy benefit provider channel. These developments highlight the company’s recent achievements in financial growth and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.